Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. develops and licenses DehydraTECH, a patented oral drug delivery formulation and processing platform designed to improve how active pharmaceutical ingredients enter the bloodstream. News about LEXX centers on GLP-1 drug delivery research, DehydraTECH-semaglutide compositions, preclinical and human study updates, intellectual property activity, and pharmaceutical partner evaluations under material transfer arrangements.
Company updates also cover Lexaria's investor communications, oral drug delivery market commentary, and applications of DehydraTECH across pharmaceuticals, nutraceuticals, over-the-counter products, and consumer formats. Recurring themes include bioabsorption, tolerability, blood-brain-barrier delivery, research laboratory activity, and the company's IP licensing business model.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) announced successful stability testing for its DehydraTECHTM CBD-infused beverages, revealing a remarkable 93.4% potency retention one year post-production. This ensures excellent microbial purity and consistent CBD distribution without physical mixing, addressing common beverage degradation challenges. The technology, which significantly enhances cannabinoid absorption, is poised for broader applications, and Lexaria continues its industry leadership in innovative drug delivery systems.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) is advancing its hypertension research and development program, which includes three human clinical studies and two animal studies, alongside two antiviral drug evaluations. CEO Chris Bunka will present at the Benzinga Biotech Small Cap Conference on March 24, 2021, at 9:45 AM ET, detailing the company's DehydraTECH drug delivery technology aimed at improving the bio-absorption of active pharmaceutical ingredients. Lexaria holds 18 granted patents and approximately 60 pending, positioning itself strongly in the biotech sector.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) reports progress in two of four planned antiviral studies using its DehydraTECH™ technology targeting SARS-CoV-2. The studies assess the effectiveness of enhanced formulations of antiviral drugs, including Remdesivir, in animal and human cell cultures. Results from the animal study (VIRAL-A20-2) are expected by late May, while human cell evaluations (VIRAL-C21-3) will commence in April, with results anticipated in June. The entire research initiative is fully funded and aims for regulatory approvals and commercial partnerships.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has announced advancements in five studies investigating DehydraTECHTM CBD as a treatment for hypertension. This includes three human clinical trials and two animal studies. The studies aim to evaluate CBD's absorption rates and its potential effects on blood pressure. Initial results from animal studies are expected by May, while human trial findings are anticipated by September. Lexaria, holding 18 international patents, aims to leverage these studies for potential commercial opportunities in the $28 billion annual hypertension market.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has expanded its hypertension R&D program, now including three human clinical studies and two animal studies to assess the effectiveness of DehydraTECH-processed CBD. CEO Chris Bunka will present at the 33rd Annual Virtual ROTH Conference from March 15-17, 2021, discussing the innovative DehydraTECH drug delivery technology that enhances bio-absorption of active pharmaceutical ingredients. The conference will host numerous companies and attract over 5,000 attendees, presenting a unique opportunity for investors.
Lexaria Bioscience (NASDAQ: LEXX) has raised $11 million to support its research and development (R&D) strategy focusing on its patented DehydraTECH technology. This technology enhances the bioavailability of drugs, particularly in the treatment of hypertension and antiviral therapies. The company is set to conduct clinical studies on a CBD formulation aimed at lowering blood pressure and is working on improving antiviral drug delivery against COVID-19. CEO Chris Bunka highlights the significant market potential, with hypertension alone representing a $30 billion industry.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has expanded its 2021 hypertension research program, now consisting of five studies aimed at evaluating DehydraTECH-processed CBD. This includes three human clinical studies (HYPER-H21-1, HYPER-H21-2, HYPER-H21-3) and two animal studies (HYPER-A21-1, HYPER-A21-2). The studies are designed to assess the efficacy of CBD on blood pressure, with initial dosing expected in early March. Lexaria aims for growth through partnerships in the hypertension and CBD pharmaceutical markets, supported by their robust patent portfolio.
Lexaria Bioscience Corp. (NASDAQ:LEXX, LEXXW) has appointed Al Reese, Jr. to its Board of Directors. With over 40 years of experience, including CFO of a Nasdaq-listed energy company, Reese brings substantial financial expertise. His background includes $10 billion in finance transactions and significant roles in investor relations. In addition, Lexaria reported that its recent NIH application was not prioritized, making funding unlikely. However, the company reassured investors that core R&D objectives remain fully funded, emphasizing resilience in its ongoing operations.
Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) has successfully closed its underwritten public offering, raising approximately $11.04 million by issuing 1,828,571 units, each consisting of one share of common stock and one warrant priced at $5.25 per unit. The warrants have an exercise price of $6.58 per share and are valid for five years. The offering was managed by H.C. Wainwright & Co., which also exercised its full option to purchase additional shares. The Company's stock began trading on Nasdaq under the symbols LEXX and LEXXW after a 1-for-30 reverse split.